ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
International Stem Cell CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026
- Market cap
- $2.27M
- P/E (TTM)
- –
- Dividend yield
- –
International Stem Cell CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomedical Market [Member] | $8.50M | $8.29M | $6.87M | $7.13M | $5.94M | $5.59M | $7.50M | $9.28M | $5.20M | $4.32M | 93.4% | +2.6% |
| Anti-aging Market [Member] | $598.00K | $795.00K | $923.00K | $1.05M | $1.24M | $1.53M | $1.97M | – | – | – | 6.6% | -24.8% |
| Anti-Aging Skincare Market [Member] | $598.00K | $795.00K | $923.00K | $1.05M | $1.24M | $1.53M | $1.97M | – | – | – | 6.6% | -24.8% |
| Cosmetic Market [Member] | – | – | – | – | – | – | $1.97M | $1.81M | $2.26M | $2.85M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomedical Market [Member] | $2.78M | $2.99M | $2.38M | $2.75M | $1.59M | $809.00K | $1.34M | $3.26M | $1.83M | $1.25M | -7.1% |
| Anti-aging Market [Member] | -$510.00K | -$602.00K | -$520.00K | -$561.00K | -$244.00K | -$217.00K | -$726.00K | – | – | – | -15.3% |
| Therapeutic Market [Member] | -$2.53M | -$2.46M | -$2.52M | -$2.37M | – | – | – | -$5.90M | -$6.39M | -$6.15M | +3.2% |
| Cosmetic Market [Member] | – | – | – | – | – | – | -$726.00K | -$825.00K | -$378.00K | $52.00K | – |
| Therapeutics Market [Member] | – | – | – | -$2.37M | -$3.27M | -$3.41M | -$6.35M | -$5.90M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic [Member] | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Clinical [Member] | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Product Sales [Member] | – | – | – | – | – | – | – | $11.09M | $7.46M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $7.84M | $7.73M | $6.55M | $7.02M | $5.92M | – | – | – | – | – | 86.1% | +1.4% |
| Asia [Member] | $719.00K | $890.00K | $726.00K | $690.00K | $806.00K | $538.00K | $540.00K | $612.00K | $728.00K | $702.00K | 7.9% | -19.2% |
| Europe [Member] | $448.00K | $407.00K | $395.00K | $393.00K | $345.00K | $290.00K | $325.00K | $293.00K | $354.00K | $362.00K | 4.9% | +10.1% |
| All Other Regions [Member] | $95.00K | $61.00K | $120.00K | $81.00K | $108.00K | $23.00K | $24.00K | $24.00K | $27.00K | $40.00K | 1.0% | +55.7% |
| North America [Member] | – | – | – | – | $5.98M | $6.28M | $8.58M | $10.16M | $6.35M | $6.06M | – | – |
From the segment and revenue-disaggregation notes of International Stem Cell's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.